Highlights
- Nerandomilast (9 mg and 18 mg bid) successfully met the primary endpoint of reducing the rate of decline in forced vital capacity (FVC) at 52 weeks in patients with idiopathic pulmonary fibrosis (IPF).
- Extended follow-up data (average 14.8 months) showed no statistically significant reduction in the composite key secondary endpoint: time to first acute exacerbation, respiratory hospitalization, or death.
- A numerical trend toward reduced mortality was observed in the 18 mg bid group (HR 0.66; 95% CI 0.41, 1.08), though it did not reach statistical significance.
- The safety profile was favorable, with treatment discontinuation rates due to adverse events being comparable to placebo, suggesting better tolerability than current standard-of-care antifibrotics.
The Unmet Need in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) remains one of the most challenging chronic respiratory conditions to manage in clinical practice. Characterized by progressive, irreversible scarring of the lung parenchyma, IPF leads to a relentless decline in lung function, worsening quality of life, and an average survival of only three to five years post-diagnosis. For over a decade, the therapeutic landscape has been dominated by two antifibrotic agents: nintedanib and pirfenidone. While these medications are effective at slowing the rate of forced vital capacity (FVC) decline, they do not halt the disease, and their clinical utility is frequently limited by significant gastrointestinal and dermatological side effects that lead to high discontinuation rates.
The search for novel therapeutic targets has led to the development of nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor. PDE4 is a key enzyme involved in the regulation of cyclic adenosine monophosphate (cAMP) levels, which in turn modulates inflammatory and fibrotic signaling pathways. By targeting the B-isoform, nerandomilast aims to maximize antifibrotic efficacy while potentially mitigating the systemic gastrointestinal side effects typically associated with non-selective PDE4 inhibition. The FIBRONEER-IPF trial was designed to evaluate whether this mechanistic approach translates into meaningful clinical benefits for patients with IPF.
Study Design and Methodology of FIBRONEER-IPF
The FIBRONEER-IPF trial was a large-scale, randomized, double-blind, placebo-controlled Phase 3 study. It enrolled a robust cohort of 1,177 patients diagnosed with IPF, randomized into three arms: placebo, nerandomilast 9 mg twice daily (bid), and nerandomilast 18 mg bid. The primary objective, which has been previously reported, was the change from baseline in FVC at week 52. However, the unique structure of the trial allowed for an extended follow-up period. Patients continued their randomized treatment until the final patient reached the 52-week mark, ensuring a database lock that captured events over a longer horizon than many traditional registrational trials.
The objectives of the current analysis were to assess the efficacy of nerandomilast over the full duration of the follow-up. The key secondary endpoint was a composite of time to the first acute exacerbation of IPF, hospitalization for a respiratory cause, or all-cause mortality. Other time-to-event endpoints, including individual components of the composite and safety parameters, were also rigorously analyzed at the final database lock.
Key Findings: Efficacy and Clinical Outcomes
The mean exposure to trial medication across all groups was approximately 14.7 to 14.9 months, providing a substantial window to observe clinical events beyond the initial 52-week primary endpoint. Despite the success of nerandomilast in slowing FVC decline, the results for the composite clinical endpoint were more nuanced.
Composite Secondary Endpoint
The hazard ratios (HR) for the key secondary endpoint—time to first acute exacerbation, respiratory hospitalization, or death—showed no significant difference between the nerandomilast groups and the placebo group. Specifically, the HR for the 9 mg bid group was 0.92 (95% CI: 0.69, 1.22), and for the 18 mg bid group, it was 0.99 (95% CI: 0.75, 1.31). These findings suggest that the reduction in FVC decline observed in the first year did not immediately translate into a reduction in these severe clinical events during the observed timeframe.
Mortality Trends
One of the most intriguing findings from the extended follow-up was the trend in mortality. While the 9 mg group showed almost no difference from placebo (HR 0.95), the 18 mg bid group demonstrated a numerical reduction in the risk of death, with a hazard ratio of 0.66 (95% CI: 0.41, 1.08). Although the 95% confidence interval crosses 1.0, indicating a lack of statistical significance, the 34% numerical reduction in mortality is clinically provocative and warrants further scrutiny in larger or longer-term real-world datasets.
Safety and Tolerability
In the management of IPF, tolerability is often as critical as efficacy. The FIBRONEER-IPF trial reported a favorable safety profile for nerandomilast. Adverse events leading to permanent treatment discontinuation occurred in 13.0% of the placebo group, 13.5% of the 9 mg group, and 16.1% of the 18 mg group. These rates are notably lower than those seen in historical trials of nintedanib and pirfenidone, where discontinuation rates due to adverse events often exceeded 20%. This suggests that nerandomilast may offer a more manageable therapeutic option for patients who struggle with the side effects of current standard-of-care treatments.
Expert Commentary: Interpreting the Disconnect
The results of FIBRONEER-IPF highlight a recurring theme in interstitial lung disease (ILD) research: the disconnect between surrogate markers (like FVC) and hard clinical outcomes (like hospitalization and death). While FVC is the gold-standard endpoint for drug approval in IPF, it is not always a perfect predictor of short-term mortality or exacerbation risk.
There are several possible reasons for the neutral result on the composite endpoint. First, the trial may not have been sufficiently powered to detect differences in these relatively infrequent events, especially within a 15-month timeframe. Second, the background therapy or the stable nature of the enrolled population might have influenced the event rates. However, the numerical signal for mortality in the 18 mg group is encouraging. It suggests that higher-dose PDE4B inhibition might provide a survival advantage that takes longer to manifest than the stabilization of lung function.
From a clinical perspective, the most significant takeaway may be the safety data. If nerandomilast can provide lung function protection similar to current drugs but with a significantly lower burden of side effects, it could rapidly become a preferred first-line or add-on therapy. The ability to keep patients on treatment longer is fundamentally linked to better long-term outcomes in a progressive disease like IPF.
Conclusion and Future Directions
The FIBRONEER-IPF trial confirms that nerandomilast is a potent agent for slowing the physiological progression of idiopathic pulmonary fibrosis. While the study did not demonstrate a significant impact on the composite of exacerbations, hospitalizations, and death over a 15-month period, the numerical survival trend in the high-dose group and the drug’s excellent tolerability profile mark it as a major advancement in the field.
Future research should focus on whether nerandomilast provides synergistic effects when used in combination with existing antifibrotics and whether its benefits on clinical events become more pronounced over several years of therapy. For now, nerandomilast represents a promising new tool in the quest to transform IPF from a rapidly fatal diagnosis into a manageable chronic condition.
Funding and Trial Registration
The FIBRONEER-IPF trial was funded by Boehringer Ingelheim. ClinicalTrials.gov Identifier: NCT04827537.
References
- Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026. PMID: 41738262.
- Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
- King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
- Martinez FJ, Richeldi L, Walsh SLF, et al. Nerandomilast for Idiopathic Pulmonary Fibrosis: Phase 3 Trial Results. New England Journal of Medicine (Reference to primary 52-week data).
